These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29641946)

  • 1. Preventing Today's Survivors of Breast Cancer From Becoming Tomorrow's Cardiac Patients.
    Nowsheen S; Duma N; Ruddy KJ
    J Oncol Pract; 2018 Apr; 14(4):213-214. PubMed ID: 29641946
    [No Abstract]   [Full Text] [Related]  

  • 2. Docetaxel: today's results and tomorrow's promises.
    Hortobagyi GN
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):11-4. PubMed ID: 9364535
    [No Abstract]   [Full Text] [Related]  

  • 3. Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues.
    Khouri MG; Douglas PS; Mackey JR; Martin M; Scott JM; Scherrer-Crosbie M; Jones LW
    Circulation; 2012 Dec; 126(23):2749-63. PubMed ID: 23212997
    [No Abstract]   [Full Text] [Related]  

  • 4. That an Ounce of Prevention Is Worth a Pound of Cure Is Certainly True for Patients With Breast Cancer.
    Lenihan DJ
    J Oncol Pract; 2018 Apr; 14(4):216. PubMed ID: 29641948
    [No Abstract]   [Full Text] [Related]  

  • 5. Utilization of Cardiac Surveillance Tests in Survivors of Breast Cancer and Lymphoma After Anthracycline-Based Chemotherapy.
    Ruddy KJ; Sangaralingham LR; Van Houten H; Nowsheen S; Sandhu N; Moslehi J; Neuman H; Jemal A; Haddad TC; Blaes AH; Villarraga HR; Thompson C; Shah ND; Herrmann J
    Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e005984. PubMed ID: 32106704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse effects of non-hormonal pharmacological interventions in breast cancer survivors, suffering from hot flashes: A systematic review and meta-analysis.
    Hervik JB; Stub T
    Breast Cancer Res Treat; 2016 Nov; 160(2):223-236. PubMed ID: 27709351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin/paclitaxel combination does not expose breast cancer patients to excessive cardiac risk.
    Oncology (Williston Park); 2001 Jul; 15(7):830. PubMed ID: 11499684
    [No Abstract]   [Full Text] [Related]  

  • 8. Risk of heart disease following treatment for breast cancer - results from a population-based cohort study.
    Yang H; Bhoo-Pathy N; Brand JS; Hedayati E; Grassmann F; Zeng E; Bergh J; Bian W; Ludvigsson JF; Hall P; Czene K
    Elife; 2022 Mar; 11():. PubMed ID: 35293856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there any cumulative dose for trastuzumab?
    Mutlu H; Coşkun HŞ
    J Oncol Pharm Pract; 2015 Dec; 21(6):468-70. PubMed ID: 24903272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tomorrow's targeted therapies in breast cancer patients: what is the risk for increased radiation-induced cardiac toxicity?
    Magné N; Chargari C; MacDermed D; Conforti R; Védrine L; Spano JP; Khayat D
    Crit Rev Oncol Hematol; 2010 Dec; 76(3):186-95. PubMed ID: 20138541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comment on a meta-analysis evaluating the cardiac toxicity of lapatinib in patients with breast cancer and other HER2-positive cancers.
    Tan Q; Wei C
    Breast Cancer Res Treat; 2018 Apr; 168(3):769-770. PubMed ID: 29330623
    [No Abstract]   [Full Text] [Related]  

  • 12. Diagnosis of Persistent Chemotherapy-Induced Alopecia in Breast Cancer Survivors.
    Freites-Martinez A; Shapiro J
    JAMA Dermatol; 2022 Jun; 158(6):704. PubMed ID: 35507353
    [No Abstract]   [Full Text] [Related]  

  • 13. Chemotherapy-induced cardiotoxicity in women.
    Dempsey KS
    Crit Care Nurs Clin North Am; 2008 Sep; 20(3):343-50. PubMed ID: 18644518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors.
    Burstein HJ; Winer EP
    J Clin Oncol; 2007 Sep; 25(25):3797-9. PubMed ID: 17761968
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients.
    Reneau JC; Asante D; van Houten H; Sangaralingham LR; Buadi FK; Lerman A; Herrmann J
    Am J Hematol; 2017 Feb; 92(2):E15-E17. PubMed ID: 27813147
    [No Abstract]   [Full Text] [Related]  

  • 16. Canadian children: will today's "couch potatoes" be tomorrow's cardiac patients?
    Goldman B
    CMAJ; 1988 Apr; 138(7):648-9. PubMed ID: 3355938
    [No Abstract]   [Full Text] [Related]  

  • 17. Symptom burden among older breast cancer survivors: The Thinking and Living With Cancer (TLC) study.
    Mandelblatt JS; Zhai W; Ahn J; Small BJ; Ahles TA; Carroll JE; Denduluri N; Dilawari A; Extermann M; Graham D; Hurria A; Isaacs C; Jacobsen PB; Jim HSL; Luta G; McDonald BC; Patel SK; Root JC; Saykin AJ; Tometich DB; Zhou X; Cohen HJ
    Cancer; 2020 Mar; 126(6):1183-1192. PubMed ID: 31860135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors.
    Brockstein BE; Smiley C; Al-Sadir J; Williams SF
    Bone Marrow Transplant; 2000 Apr; 25(8):885-94. PubMed ID: 10808211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of ultrasensitive cardiac Troponin I levels in patients with breast cancer during chemotherapy.
    Moreno R; Costa RG; Mazar RC; Silva MB; de Souza MG; Murad N; Feder D; Azzalis LA; Alves BC; Gehrke FS; Adami F; Fonseca FL
    Clin Chim Acta; 2014 Jan; 428():70-1. PubMed ID: 24220552
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term risk of congestive heart failure in younger breast cancer survivors: A nationwide study by the SMARTSHIP group.
    Lee J; Hur H; Lee JW; Youn HJ; Han K; Kim NW; Jung SY; Kim Z; Kim KS; Lee MH; Han SH; Jung SH; Chung IY
    Cancer; 2020 Jan; 126(1):181-188. PubMed ID: 31454422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.